Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neovascularization

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    171 result(s) found for: Neovascularization. Displaying page 5 of 9.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2007-005798-75 Sponsor Protocol Number: NVI-114 Start Date*: 2008-02-21
    Sponsor Name:Neo Vista Inc.
    Full Title: Estudio prospectivo, aleatorizado y controlado de Epi-Rad90™, sistema oftálmico para el tratamiento de la neovascularización coroidea subfoveolar asociada a degeneración macular de tipo húmedo asoc...
    Medical condition: neovascularización coroidea subfoveolar asociada a degeneración macular de tipo húmedo asociada a la edad
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-001235-30 Sponsor Protocol Number: MSI-1256F-302 Start Date*: 2005-10-26
    Sponsor Name:Genaera Corporation
    Full Title: A Phase 3 Multicenter, Randomized, Double-Masked, Controlled Study of Squalamine Lactate (MSI-1256F) for Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Re...
    Medical condition: Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001790-16 Sponsor Protocol Number: LSC2-II-01 Start Date*: 2019-01-07
    Sponsor Name:RHEACELL GmbH & Co. KG
    Full Title: AN INTERVENTIONAL, OPEN-LABEL, MULTICENTER PHASE I/IIA CLINICAL TRIAL TO INVESTIGATE THE SAFETY AND EFFICACY OF ASCENDING DOSES OF ALLOGENEIC ABCB5-POSITIVE LIMBAL STEM CELLS (LSC2) FOR THE TREATME...
    Medical condition: Limbal stem cell deficiency (LSCD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10072138 Limbal stem cell deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001970-41 Sponsor Protocol Number: 0504-19 Start Date*: 2022-03-18
    Sponsor Name:Intas Pharmaceuticals Ltd.
    Full Title: A Double Masked, Parallel Group, Randomized, Multicenter, Clinical Study to Compare Efficacy and Safety of Intas Ranibizumab with Lucentis® in Patients with Neovascular (Wet) Age-Related Macular De...
    Medical condition: Neovascular (Wet) Age-Related Macular Degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    27.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) PL (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004486-13 Sponsor Protocol Number: QL1205-002 Start Date*: 2019-04-18
    Sponsor Name:Qilu Pharmaceutical Co., Ltd.
    Full Title: A Randomized, Phase 3, Double-masked, Parallel-group, Multicenter Study to Compare Efficacy and Safety of QL1205 Versus Lucentis® in Subjects With Neovascular Age-related Macular Degeneration
    Medical condition: Subjects With Wet (neovascular) Age-related Macular Degeneration (wAMD), aged ≥50 years
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) CZ (Completed) LV (Completed) PL (Completed) BG (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000519-42 Sponsor Protocol Number: OPH1008 Start Date*: 2015-10-26
    Sponsor Name:OPHTHOTECH CORPORATION
    Full Title: Role of multimodal imaging in the evaluation of anatomic alterations in neovascular Age-Related Macular Degeneration (AMD) subjects: 18 month Phase 2a open label study of Fovista® (anti-PDGF therap...
    Medical condition: Subfoveal choroidal neovascularization secondary to Age-Related Macular Degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    18.0 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000722-31 Sponsor Protocol Number: EOP1014 Start Date*: 2006-08-17
    Sponsor Name:(OSI) Eyetech, Inc
    Full Title: An Exploratory randomized, double-masked, multi-center, multi-dose comparative trial, in parallel groups, to explore the safety and efficacy of three different doses of intravitreous injections of ...
    Medical condition: Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    8.0 10064930 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004530-11 Sponsor Protocol Number: ALT-L9-03 Start Date*: 2022-04-21
    Sponsor Name:Altos Biologics Inc.
    Full Title: A Randomized, Phase 3, Double Masked, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of ALT L9 Versus Eylea® in Patients With Neovascular Age Related Macular Degeneration (ALT...
    Medical condition: Neovascular Age Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) SK (Completed) LV (Completed) AT (Completed) ES (Ongoing) BG (Completed) EE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004132-37 Sponsor Protocol Number: SCD411-CP101 Start Date*: 2020-07-22
    Sponsor Name:SamChunDang Pharm. Co. Ltd.
    Full Title: A Phase III Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity between SCD411 and Eylea® in Subjects wi...
    Medical condition: Neovascular Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) BG (Completed) PL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2015-000518-23 Sponsor Protocol Number: OPH1007 Start Date*: 2015-10-20
    Sponsor Name:OPHTHOTECH CORPORATION
    Full Title: A phase 2b randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista® (Anti-PDGFBB pegylated aptamer) administered in combination w...
    Medical condition: Subfoveal neovascular age-related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    18.1 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) EE (Prematurely Ended) CZ (Prematurely Ended) HR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004934-14 Sponsor Protocol Number: EMASPK01 Start Date*: 2014-01-15
    Sponsor Name:Institut klinické a experimentální medicíny
    Full Title: EVEROLIMUS VERSUS MYCOPHENOLIC ACID IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE DIFFERENCES IN RETINAL NEOVASCULARIZATION IN PATIENTS WITH DIABETIC RETINOPATHY
    Medical condition: simultaneous pancreas/kidney allograft transplantation
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004865 10048622 Pancreatic transplant LLT
    16.1 100000004865 10023438 Kidney transplant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002351-33 Sponsor Protocol Number: 1299 Start Date*: 2006-08-09
    Sponsor Name:AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
    Full Title: Evaluation of safety and efficacy of intravitreal bevacizumab for macular edema, retinal or choroidal neovascularization or neovascular glaucoma
    Medical condition: Macular oedema
    Disease: Version SOC Term Classification Code Term Level
    6.1 10047060 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004758-27 Sponsor Protocol Number: V1 Start Date*: 2013-01-30
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Augenheilkunde
    Full Title: fMRI analysis of the visual cortex in neovascular age-related macular degeneration
    Medical condition: 20 patients with neovascular age-related macular degeneration will be examined before and after 3 monthly administered intravitreal ranibizumab injections according to the label with 7 tesla magnet...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004769-15 Sponsor Protocol Number: V1.2 Start Date*: 2013-12-13
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Augenheilkunde
    Full Title: fMRI analysis of the visual cortex in neovascular Age-related Macular Degeneration
    Medical condition: 20 patients with neovascular age-related macular degeneration will be examined before and after 3 monthly administered intravitreal ranibizumab injections according to the label with 3 tesla magnet...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004874-14 Sponsor Protocol Number: 2007-08-16 REPAIR-ACS Start Date*: 2008-06-09
    Sponsor Name:Cardiology, J. W. Goethe University Frankfurt
    Full Title: Doppel-blinde, randomisierte, kontrollierte Studie zur Erfassung des Effektes einer intrakoronaren Applikation von Knochenmark-Progenitorzellen auf die koronare Flußreserve bei Patienten mit akutem...
    Medical condition: Patients with acute coronary syndrome (NSTEMI) due to coronary artery disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003029-40 Sponsor Protocol Number: IOBA-01-2016 Start Date*: 2017-02-14
    Sponsor Name:IOBA - University of Valladolid
    Full Title: Phase II safety assessment of intravitreal injection of mesenchymal stem cells for acute non arteritic anterior ischemic optic neuropathy (NAION)
    Medical condition: Non arteritic anterior ischemic optic neuropathy (NAION)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003976-36 Sponsor Protocol Number: CBPD952ABE02 Start Date*: 2006-09-01
    Sponsor Name:Professor Anita Leys - Dienst Oftalmologie UZ St. Rafaël
    Full Title: An academic monocenter study assessing the safety and efficacy of Lucentis (ranizumab 0.3 mg) administered in conjunction with photodynamic therapy with Visudyne in patients with occult or predomi...
    Medical condition: Male and female patients ≥50 years of age with subfoveal choroidal neovascularisation lesions secondary to age related macular degeneration, either predominantly classic or occult with no classic c...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000642-35 Sponsor Protocol Number: HL217-201 Start Date*: 2019-09-19
    Sponsor Name:HANLIM PHARM CO., LTD
    Full Title: A phase IIa randomized, double-blind, multicentre study to evaluate safety and efficacy of HL217 topical ophthalmologic solution in the treatment of exudative Age-Related Macular Degeneration (AMD)
    Medical condition: AMD (age-related macular degeneration)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10068530 Macular degeneration progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001492-37 Sponsor Protocol Number: Z-AMD Start Date*: 2019-11-01
    Sponsor Name:Oslo University Hospital
    Full Title: Zoledronic acid as adjuvant therapy in neovascular Age-related Macular Degeneration (The Z-AMD study): a randomized controlled pilot study
    Medical condition: Neovascular Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003133-42 Sponsor Protocol Number: 1672_2019 Start Date*: 2020-02-14
    Sponsor Name:Medical University of Vienna, Department of Ophthalmology and Optometry
    Full Title: Personalized treatment aided by automated analysis of fluid in active neovascular age-related macular degeneration (nAMD) in a prospective, multicenter, randomized study
    Medical condition: Nevoascular age related macular degneration (nAMD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 09 17:24:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA